JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) marked an important juncture in. BNP in 11, participants without cardiovascular disease in the JUPITER Un Estudio Intervencionista que Evalúa Rosuvastatina (JUPITER, Justification. Desde que en el estudio JUPITER 34 se detectó una mayor incidencia de DM en el grupo con rosuvastatina 35, varios metaanálisis han.

Author: Akinot Shaktimi
Country: Guinea-Bissau
Language: English (Spanish)
Genre: Travel
Published (Last): 1 August 2010
Pages: 253
PDF File Size: 17.55 Mb
ePub File Size: 14.91 Mb
ISBN: 990-9-47389-524-5
Downloads: 45598
Price: Free* [*Free Regsitration Required]
Uploader: Jujora

However, the reduction in total and cardiovascular mortality was not significant due to the small sample size. Several cardiovascular outcome studies estuio confirmed the beneficial effects that had been anticipated from vascular imaging studies.

Rosyvastatina patients should be considered for treatment with rosuvastatin. When hsCRP is included in enrolment of primary prevention, rosuvastatin produced greater benefit when compared with other statins.

Early statin therapy restores endothelial function in children with familial hypercholesterolemia. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events.

One unique effect of rosuvastatin is the dose dependent transient proximal isolated low- molecular-weight proteinuria which appears to have no effect on glomerular function. An Assessment of Survival and Cardiovascular Events investigated the effects of rosuvastatin on cardiovascular risk in haemodialysis patients.

  LTC 9215 00 PDF

Scandinavian Simvastatin Survival Study Group.

Rediscovering bile acid sequestrants. Table 4 Adverse outcomes of statins. Table 5 shows drugs which can interact with rosuvastatin. In all of them, participants who achieved low concentrations of hsCRP in addition to low values of the lipid parameters of interest had the best outcome.

This in turn reduces endothelial dysfunction that has been implicated in atherosclerosis. Journal of the American College of Cardiology. Drugs affected by co-administration with rosuvastatin. Rosuvastatin efficacy, safety and clinical effectiveness.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

In the same study rosuvastatin 20 mg achieved similar LDL-C reduction as atorvastatin 80 mg. Combination of statins with other medications may lead to increased risk if these medication increase plasma concentrations of the statins.

Rosuvastatin in women Previous primary prevention trials have poorly demonstrated reduction in coronary events in women. Its benefits against cost in patients with lower cardiovascular risk remain an issue of debate. Rosuvastatin is less lipophilic than other statins such as atorvastatin and simvastatin but more lipophilic than pravastatin. A possible exception is pitavastatin. Koenig W, Ridker PM.

Rosuvastatin in children Studies roauvastatina children with heterozygous FH have shown the estuvio and efficacy of statins, including their effect on carotid intima thickness and arterial flow mediated dilation. Cholesterol Lowering Effects of Rosuvastatin compared with Atorvastatin in patients with type 2 diabetes. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes—CORALL study.


Its potential impact in primary and secondary prevention of cardiovascular disease in different groups including heart failure, elderly, renal failure and diabetes, and also in combination with other lipid lowering drugs is the subject of ongoing clinical studies.

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease

Intensive therapy with rosuvastatin may yield similar benefits. Previous studies rosuvastatinq identified ApoB: A number of reports are emerging about intermittent or pulsed therapy which is better tolerated yet maintains reasonable lipid control. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase The absolute risk of rosvastatina diabetes was 0. Economic evaluations show that intensive lipid lowering is a cost effective treatment for very high risk patients groups including those with ACS, heterozygous FH and diabetes.

Furthermore the combination of rosuvastatin with fenofibric acid was well tolerated and as safe as each drug used as monotherapy.